Glucagon-like peptide-2 regulates release of chylomicrons from the intestine

Gastroenterology

Volumn 147, Issue 6, 2014, Pages 1275-1284.e4

  Dash, Satya ^a   Xiao, Changting ^a   Morgantini, Cecilia ^a   Connelly, Philip W ^a,b   Patterson, Bruce W ^c   Lewis, Gary F ^a,d  

^a UNIVERSITY OF TORONTO   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Enterocyte; Fatty Acid; Human Trial; Plasma Lipid

Indexed keywords

AMINO ACID; APOLIPOPROTEIN B100; APOLIPOPROTEIN B48; CHYLOMICRON; GLUCAGON; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; GROWTH HORMONE; INSULIN; LEUCINE; LIPID; PLACEBO; RETINOL PALMITATE; SOMATOSTATIN; STABLE ISOTOPE; TRIACYLGLYCEROL; FAT INTAKE; GASTROINTESTINAL AGENT; RETINOL;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLAMP; CONTROLLED STUDY; CROSSOVER PROCEDURE; ENTERIC FEEDING; GLUCOSE BLOOD LEVEL; HUMAN; INTESTINAL SECRETION; LIPID DIET; LIPID STORAGE; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN SECRETION; MALE; MATHEMATICAL MODEL; NORMAL HUMAN; PANCREATIC CLAMP; RANDOMIZED CONTROLLED TRIAL; REGULATORY MECHANISM; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE; TRIACYLGLYCEROL BLOOD LEVEL; VALIDATION STUDY; VITAMIN BLOOD LEVEL; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DYSLIPIDEMIAS; FAT INTAKE; INTESTINE; METABOLISM; MIDDLE AGED; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL;

ADULT; APOLIPOPROTEIN B-100; APOLIPOPROTEIN B-48; CHYLOMICRONS; CROSS-OVER STUDIES; DIETARY FATS; DYSLIPIDEMIAS; GASTROINTESTINAL AGENTS; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE; HUMANS; INTESTINES; MALE; MIDDLE AGED; SINGLE-BLIND METHOD; TRIGLYCERIDES; VITAMIN A;

EID: 84913568983     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.08.037     Document Type: Article

References (41)

1. C. Xiao, J. Hsieh, and K. Adeli Gut-liver interaction in triglyceride-rich lipoprotein metabolism Am J Physiol Endocrinol Metab 301 2011 E429 E446
2. X. Pan, and M.M. Hussain Gut triglyceride production Biochim Biophys Acta 1821 2012 727 735
3. M.D. Robertson, M. Parkes, and B.F. Warren Mobilisation of enterocyte fat stores by oral glucose in humans Gut 52 2003 834 839
4. R.N. Chavez-Jauregui, R.D. Mattes, and E.J. Parks Dynamics of fat absorption and effect of sham feeding on postprandial lipema Gastroenterology 139 2010 1538 1548
5. K. Evans, P.J. Kuusela, and M.L. Cruz Rapid chylomicron appearance following sequential meals: effects of second meal composition Br J Nutr 79 1998 425 429
6. D.J. Drucker, and B. Yusta Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2 Annu Rev Physiol 76 2014 561 583
7. J. Hsieh, C. Longuet, and A. Maida Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36 Gastroenterology 137 2009 997 1005 1005 e1-4
8. G.J. Hein, C. Baker, and J. Hsieh GLP-1 and GLP-2 as yin and yang of intestinal lipoprotein production: evidence for predominance of GLP-2-stimulated postprandial lipemia in normal and insulin-resistant states Diabetes 62 2012 373 381
9. P.B. Jeppesen, M. Pertkiewicz, and B. Messing Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure Gastroenterology 143 2012 1473 1481 e3
10. P.B. Jeppesen, P. Lund, and I.B. Gottschalck Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function Gastroenterol Res Pract 2009 2009 616054
11. P.B. Jeppesen Pharmacologic options for intestinal rehabilitation in patients with short bowel syndrome JPEN J Parenter Enteral Nutr 38 Suppl 2014 45S 52S
12. J.J. Meier, M.A. Nauck, and A. Pott Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans Gastroenterology 130 2006 44 54
13. C. Xiao, R.H. Bandsma, and S. Dash Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans Arterioscler Thromb Vasc Biol 32 2012 1513 1519
14. S. Lemieux, R. Fontani, and K.D. Uffelman Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins J Lipid Res 39 1998 1964 1971
15. C. Xiao, S. Dash, and C. Morgantini New and emerging regulators of intestinal lipoprotein secretion Atherosclerosis 233 2014 608 615
16. E. Morel, S. Demignot, and D. Chateau Lipid-dependent bidirectional traffic of apolipoprotein B in polarized enterocytes Mol Biol Cell 15 2004 132 141
17. X. Guan, B. Stoll, and X. Lu GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1 Gastroenterology 125 2003 136 147
18. L. Bremholm, M. Hornum, and U.B. Andersen The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients Regul Pept 168 2011 32 38
19. P. Tso, and J.A. Balint Formation and transport of chylomicrons by enterocytes to the lymphatics Am J Physiol 250 1986 G715 G726
20. M. Pavlic, C. Xiao, and L. Szeto Insulin acutely inhibits intestinal lipoprotein secretion in humans in part by suppressing plasma free fatty acids Diabetes 59 2010 580 587
21. H. Duez, B. Lamarche, and R. Valero Both intestinal and hepatic lipoprotein production are stimulated by an acute elevation of plasma free fatty acids in humans Circulation 117 2008 2369 2376
22. C. Xiao, M. Pavlic, and L. Szeto Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans Diabetes 60 2011 383 390
23. J. Hsieh, C. Longuet, and C.L. Baker The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice Diabetologia 53 2010 552 561
24. C. Xiao, S. Dash, and C. Morgantini Sitagliptin, a dipeptidyl peptidase-4 inhibitor, acutely inhibits intestinal lipoprotein particle secretion in healthy humans Diabetes 63 2014 2394 2401
25. B. Hartmann, M.B. Harr, and P.B. Jeppesen In vivo and in vitro degradation of glucagon-like peptide-2 in humans J Clin Endocrinol Metab 85 2000 2884 2888
26. B. Hartmann, J. Thulesen, and K.J. Hare Immunoneutralization of endogenous glucagon-like peptide-2 reduces adaptive intestinal growth in diabetic rats Regul Pept 105 2002 173 179
27. E.D. Shin, J.L. Estall, and A. Izzo Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice Gastroenterology 128 2005 1340 1353
28. J. Bahrami, B. Yusta, and D.J. Drucker ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel Gastroenterology 138 2010 2447 2456
29. S.J. Lee, J. Lee, and K.K. Li Disruption of the murine Glp2r impairs Paneth cell function and increases susceptibility to small bowel enteritis Endocrinology 153 2012 1141 1151
30. J. Crosby, G.M. Peloso, and P.L. Auer Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 2014 22 31
31. A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 2014 32 41
32. D.B. Henriksen, P. Alexandersen, and B. Hartmann Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD Bone 45 2009 833 842
33. A.L. Buchman, S. Katz, and J.C. Fang Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease Inflamm Bowel Dis 16 2010 962 973
34. L. Bremholm, M. Hornum, and U.B. Andersen The effect of glucagon-like peptide-2 on mesenteric blood flow and cardiac parameters in end-jejunostomy short bowel patients Regul Pept 168 2011 32 38
35. P.B. Jeppesen, P. Lund, and I.B. Gottschalck Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function Gastroenterol Res Pract 2009 2009 616054
36. C. Xiao, R.H. Bandsma, and S. Dash Exenatide, a glucagon-like peptide-1 receptor agonist, acutely inhibits intestinal lipoprotein production in healthy humans Arterioscler Thromb Vasc Biol 32 2012 1513 1519
37. D.J. Drucker, and B. Yusta Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2 Annu Rev Physiol 76 2014 561 583
38. C. Xiao, M. Pavlic, and L. Szeto Effects of acute hyperglucagonemia on hepatic and intestinal lipoprotein production and clearance in healthy humans Diabetes 60 2011 383 390
39. R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J Lipid Res 47 2006 2738 2753
40. S. Lemieux, R. Fontani, and K.D. Uffelman Apolipoprotein B-48 and retinyl palmitate are not equivalent markers of postprandial intestinal lipoproteins J Lipid Res 39 1998 1964 1971
41. A.L. Sowell, D.L. Huff, and P.R. Yeager Retinol, alpha-tocopherol, lutein/zeaxanthin, beta-cryptoxanthin, lycopene, alpha-carotene, trans-beta-carotene, and four retinyl esters in serum determined simultaneously by reversed-phase HPLC with multiwavelength detection Clin Chem 40 1994 411 416